What insurance policy changes affect code L80?

There are 6 tracked policy changes affecting code L80, including updates from Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code L80?

Payers that have issued tracked updates for code L80 include: Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code L80 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code L80. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code L80?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

L80 Insurance Policy Changes

ICD-10 L80 is officially defined as "Vitiligo." code L80 is referenced in 6 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code L80 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Oct 22, 2026Medium impact
Light and Laser Therapies for Dermatologic Conditions 8.01.21
Policy 8.01.21 considers UVB light, PUVA, UVA light, FDA-cleared targeted excimer phototherapy, home UVB phototherapy, 5-aminolevulinic acid photodynamic therapy and pulsed dye laser for port wine birthmarks medically appropriate when the listed criteria are met. It considers targeted phototherapy for first-line treatment of mild psoriasis, generalized psoriasis or psoriatic arthritis, and vitiligo investigational, along with photodynamic therapy with topical preparations for other conditions and light or laser treatment of acne. The current effective date is October 22, 2026, and the 10/22/26 annual review left the policy intent unchanged.
Excellus BlueCross BlueShield · Effective Sep 17, 2026Medium impact
Cosmetic and Reconstructive Procedures 7.01.11
Policy 7.01.11 treats reconstructive procedures as medically appropriate only when a functional deficit is documented, a reconstructive purpose is documented, and the indication-specific criteria are met, such as the criteria for acne surgery, benign skin lesion removal, breast procedures, pectus repair, dermabrasion, otoplasty, hypertrophic scar revision, and vulvectomy as part of cancer surgery. Procedures that reshape structures to improve appearance or self-esteem without a functional deficit, including breast augmentation with implants, breast lift, rhytidectomy, tattooing, chemical peels, hair transplant, hair removal, and non-surgical body sculpting, are considered cosmetic and not medically necessary for all indications unless the reconstructive criteria are met. Cryotherapy for acne, certain hyperhidrosis treatments, and autologous melanocyte transplantation for vitiligo are investigational.
Aetna · Identified Aug 19, 2026Medium impact
Vitiligo (CPB 0422, reviewed 2026-07-16)
Aetna considers PUVA, excimer laser, or office-based or home narrow-band UVB medically necessary for vitiligo when the member has had an inadequate response to topical tacrolimus, topical and systemic corticosteroids, or topical ruxolitinib (Opzelura). Continued PUVA or narrow-band UVB therapy is considered not medically necessary unless there is some follicular pigmentation after 6 months of therapy (8 to 10 treatments per month). Aetna considers the listed gene polymorphism tests, IL-17 measurement, and interventions such as apremilast, CAR-T-cell therapy, and platelet-rich plasma experimental, investigational, or unproven, and considers micropigmentation (tattooing) and depigmentation with monobenzone cosmetic.
Aetna · Identified Aug 15, 2026Medium impact
Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)
Aetna's clinical policy bulletin for carbon dioxide laser (CPB 0427) lists the uses it considers medically necessary: condyloma, pelvic pain associated with endometriosis, primary penile tumors (clinical stage Tis, Ta, and T1 Grade 1 to 2), refractory plantar warts, removal of actinic keratoses for members who meet CPB 0567 criteria, removal of superficial basal cell carcinomas, and fractional carbon dioxide laser for hypertrophic burn, traumatic, and surgical scars when conventional therapies have failed. Aetna considers carbon dioxide laser experimental, investigational, or unproven for a list of other indications, including hidradenitis suppurativa, male androgenetic alopecia, onychomycosis, port wine stains, stress urinary incontinence, and vaginal atrophy. Aetna considers carbon dioxide laser treatment of other actinic lesions cosmetic.
Aetna · Identified Aug 12, 2026Medium impact
Blood and Adipose Tissue Derived Products for Selected Indications (CPB 0784, reviewed 2025-11-19)
Clinical Policy Bulletin 0784 considers the following experimental, investigational, or unproven because their effectiveness has not been established: autologous blood injection and platelet-poor or platelet-rich plasma injection for all indications, plus specific listed uses of autologous platelet gel, adipose-tissue-derived stem cell injections, autologous fat injection and other blood-derived products. Listed uses include platelet-rich plasma for rotator cuff injuries, osteoarthritis and plantar fasciitis, autologous platelet gel after total knee arthroplasty and for diabetic foot ulcer, and autologous fat injection for carpometacarpal arthritis of the thumb and velopharyngeal insufficiency. The policy also lists CPT, HCPCS and ICD-10 codes as not covered for the indications it lists.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Targeted Phototherapy and Psoralen with Ultraviolet A for Vitiligo
Targeted phototherapy is considered investigational for the treatment of vitiligo. PUVA (psoralen plus ultraviolet A) for vitiligo that is not responsive to other forms of conservative therapy, such as topical corticosteroids, coal/tar preparations, and ultraviolet light, may be considered medically necessary. PUVA is generally not recommended for home therapy, and the individual needs to be assessed on a regular basis for effectiveness of the therapy and development of side effects.

Watch L80

Get one email when a payer policy names L80, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Light and Laser Therapies for Dermatologic Conditions 8.01.21

Cosmetic and Reconstructive Procedures 7.01.11

Vitiligo (CPB 0422, reviewed 2026-07-16)

Carbon Dioxide Laser (CPB 0427, reviewed 2026-07-08)

Blood and Adipose Tissue Derived Products for Selected Indications (CPB 0784, reviewed 2025-11-19)

Targeted Phototherapy and Psoralen with Ultraviolet A for Vitiligo

What insurance policy changes affect code L80?

Which payers have updated policy for code L80?

How do I get notified when code L80 policy changes?

Why do payers change policies for code L80?